Perspective Therapeutics News

Truist Financial Remains a Buy on Perspective Therapeutics (CATX)

TipRanksNov 12 20:27 · Ratings

Here Are the Major Earnings After the Close Today

Seeking AlphaNov 12 14:00

Earnings Preview: CATX to Report Financial Results Post-market on November 12

$Perspective Therapeutics(CATX.US)$ is scheduled to release its financial results post-market on November 12 ET. Earnings PreviewAnalysts estimate $Perspective Therapeutics(CATX.US)$ to post revenue

Futu NewsNov 7 09:00

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

GlobeNewswireOct 31 19:00

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

BenzingaOct 31 03:12

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

GlobeNewswireOct 29 19:00

UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus

Seeking AlphaOct 25 03:32

Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $20

Futu NewsOct 24 20:31 · Ratings

Perspective Therapeutics Price Target Announced at $20.00/Share by UBS

Dow JonesOct 24 19:58 · Ratings

Perspective Therapeutics Announced Six Updates On The Company's Radiopharmaceutical Programs Being Presented At The 37th Annual Congress Of The European Association Of Nuclear Medicine In Germany

BenzingaOct 23 19:11

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating

Futu NewsOct 17 19:36 · Ratings

Perspective Therapeutics Begins Shipping Investigational Products From State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

GlobeNewswireOct 16 19:00

Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $22

Futu NewsOct 14 20:31 · Ratings

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Futu NewsOct 14 19:31 · Ratings

Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies

Yahoo FinanceOct 12 22:18

A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $21 to $22

Futu NewsOct 12 21:00 · Ratings

Top Midday Decliners

MT NewswiresOct 12 02:16

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Early-Stage Drug Results for Melanoma Treatment

TipRanksOct 12 02:05 · Ratings

Perspective Therapeutics Analyst Ratings

BenzingaOct 12 01:47 · Ratings

Perspective Therapeutics Shares Fall After Melanoma Study Data Analysis

WSJOct 12 00:58